Zhou Hui, Wang Anlan, Huang Zhihua, Zhou Wenwei
Department of Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan 410006, P.R.China.
Zhongguo Fei Ai Za Zhi. 2004 Jun 20;7(3):240-2. doi: 10.3779/j.issn.1009-3419.2004.03.14.
To observe and compare the efficacy and safety of IEP and EP regimens for small cell lung cancer (SCLC).
Sixty-four patients with SCLC pathologically proved were randomly divided into IEP group ( n =32) and EP group ( n =32).
All the 64 patients were evaluable for response and toxicity. In IEP group, the total responsive rate, responsive rates of limited-stage patients and extensive-stage patients were 84.4%(27/32), 100.0%(15/15) and 70.6%(12/17) respectively; while in EP group, those were 75.0%(24/32), 85.7%(12/14) and 66.7% (12/18) respectively. The median duration of remission was 6 months and 1-year survival rate was 62.5% in IEP group, and 5 months and 56.2% in EP group. There was no significant difference in response rate, median duration of remission and 1-year survival between the two groups ( P > 0.05). The main toxicity was myelosuppression. Incidences of leukopenia at grade III-IV, nausea, vomiting and alopecia were significantly higher in the IEP arm than those in the EP arm ( P < 0.01 ).
High response rates and tolerable toxicities are attainable for small cell lung cancer treated with IEP and EP. IEP regimen shows a similar response rate compared with EP regimen. They might be considered as relevant regimens in initial patients with small cell lung cancer.
观察并比较IEP方案和EP方案治疗小细胞肺癌（SCLC）的疗效和安全性。
64例经病理证实的SCLC患者随机分为IEP组（n = 32）和EP组（n = 32）。
64例患者均可进行疗效和毒性评估。IEP组的总有效率、局限期患者有效率和广泛期患者有效率分别为84.4%（27/32）、100.0%（15/15）和70.6%（12/17）；而EP组分别为75.0%（24/32）、85.7%（12/14）和66.7%（12/18）。IEP组的中位缓解期为6个月，1年生存率为62.5%；EP组分别为5个月和56.2%。两组间的有效率、中位缓解期和1年生存率无显著差异（P > 0.05）。主要毒性为骨髓抑制。IEP组III-IV级白细胞减少、恶心、呕吐和脱发的发生率显著高于EP组（P < 0.01）。
IEP方案和EP方案治疗小细胞肺癌可获得较高的有效率和可耐受的毒性。IEP方案与EP方案的有效率相似。它们可被视为初治小细胞肺癌患者的相关治疗方案。
Zotero 插件